Physician Referrals to Sunstone

We deliver psychedelic-assisted therapy within a structured clinical trial setting, led by licensed professionals with extensive experience in oncology, psychiatry, and trauma-informed care.

Refer a Patient for Psychedelic-Assisted Therapy 

Patient eligibility is assessed through structured screening protocols. We prioritize informed consent, evidence-based protocols, and continuity of care throughout the treatment experience. Referring providers are kept informed at each stage of care.

If you have a patient who may be eligible, please use the referral form to initiate the process.

Want to learn more about our work at Sunstone Therapies? Please contact us.

Refer A Patient

FDA Approved Clinical Trials – Currently Recruiting

Meet Our Clinical Team

Our team is committed to safety, scientific rigor, and compassionate treatment, and coordinates with referring providers.
Manish Agrawal, M.D.
Chief Executive Officer, Co-Founder
link
Michelle Kim Leff, M.D., MBA, CAPT (ret.), USPHS
Psychiatrist
link
Willie Harrington M.D., M.S.
Lead Clinical Evaluation Specialist
link
Candace Parks
Research Director
link
Celia Leeks
Research Manager
link
Mark Bates, Ph.D.
Therapist
link
Maureen Betz, L.C.S.W.-C
Therapist
link
Betsy Jenkins, L.C.P.C
Therapist
link
Jess Jones, L.C.S.W.-C
Therapist
link
Bob Koffman, M.D., M.P.H.
Therapist and Military Liaison
link
Sara So, L.C.P.C
Staff Therapist
link
Norma Mancini Stevens, M.S., L.C.P.C, N.C.C.
Therapist
link
Jehenifer Fuentes
Medical Assistant
link
Katelyn Jones, RN
Patient Evaluation Specialist
link
Lindsay Amann
Clinical Research Coordinator
link
Nicole Nagelvoort
Clinical Research Coordinator
link
Rhi Trautmann, NRCPT
Clinical Research Coordinator
link
Victoria Checa
Clinical Intern
link

01

Range of Psychedelic Medicines

Sunstone Therapies offers psychedelic-assisted therapies as part of FDA-approved clinical studies to address a range of patient-specific diagnoses. Therapeutic options include various psychedelic medicines such as psilocybin, MDMA, LSD, and 5-MeO DMT.  Indications we are focusing on are Adjustment Disorder, Generalized Anxiety Disorder, Major Depressive Disorder, Post-Traumatic Stress Disorder, End of Life, and Treatment-Resistant Depression. Absolute Contraindications: Personal or family history of Bipolar Disorder, Schizophrenia, Borderline Personality Disorder, Delusional Disorder, current symptoms of Obsessive-Compulsive Disorder
02

Professionally Qualified Staff

Sunstone’s clinical team comprises licensed mental health professionals, including psychologists, psychiatrists, clinical counselors, and social workers, as well as physicians, experienced research staff, and medical assistants. Our therapists are trained to deliver psychedelic-assisted therapy with clinical precision and provide structured support throughout the preparation and integration process. Our multidisciplinary team brings more than 100 years of combined clinical and research experience. Team members hold positions at leading institutions, including the Johns Hopkins Center for Psychedelic and Consciousness Research and the Dana-Farber Cancer Institute, and have contributed to peer-reviewed journals such as JAMA Oncology, the Journal of Psychopharmacology, and the Journal of Palliative Medicine. Sunstone staff are actively shaping the future of psychedelic medicine—contributing to national standards for therapist training, board certification, CPT coding, and patient care guidelines.
03

Evidence-Based Practices

Sunstone Therapies delivers psychedelic-assisted therapy grounded in both emerging and established clinical research. As the field evolves, so does our practice. Through ongoing collaboration, training, and reflection, our team continually refines its approach to supporting patients across preparation, dosing, and integration, aligning with best practices and evolving standards of care.
04

Informed Consent and Safety Protocols

Psychedelic-assisted therapy involves distinct risks and benefits, and patients are fully informed through a structured consent and screening process. Therapists use psychometrically validated measures in conjunction with clinical interviews to assess appropriateness and identify potential contraindications. Ongoing communication with referring providers helps ensure continuity of care and supports informed, collaborative decision-making.
05

Follow-Up Care and Support

Sunstone Therapies provides resources to support patients in continuing their integration process after participating in a clinical trial. Our therapists may recommend supportive materials or connections based on individual needs. Additional community-based integration offerings are under development as part of Sunstone’s evolving model of care.
Explore the REKINDLE Study for emotional distress linked to a life-changing illness.Learn More
+